320 - YEAR IN REVIEW FOR THE CLINICAL CARDIOLOGIST - CLINICAL CARDIOLOGY

Saturday, October 25, 2025

11:15am - 12:15pm ET

Room:206AB

Co-Chair(s)

David Bewick, MD, FRCPC

MD, FRCP,FACP,FACC
CSE
Dalhousie University
Anil Gupta

Cardiologist
Trillium Health Partners

Presenter(s)

jacqueline Saw, MD, FRCPC

Clinical Professor
CAIC
University of British Columbia
John Sapp, Jr., MD (he/him/his)

Professor
CHRS
Dalhousie University
DT

Dinesh Thavendiranathan, MD, SM, FRCPC, FASE

Cardiologist
CCON
University of Toronto

Stay at the forefront of cardiovascular care with the annual "Year in Review for the Clinical Cardiologist". This session is ideal for clinicians seeking a high-yield summary of the year’s most important advances in cardiovascular medicine, delivered in an engaging and accessible format.

Designed for busy clinicians, the session emphasizes pragmatic insights and actionable “take home messages” Attendees will gain a concise overview of the latest evidence, with each key finding placed in a clear clinical context to support informed decision-making at the bedside. Each presentation concludes with practical recommendations, ensuring participants leave equipped with knowledge that can immediately enhance patient care.

In this session the following topics will be discussed:
Topic 1: Controversies in the young patient with a NSTEMI
Topic 2: Controversies in arrhythmia management
Topic 3: Cardio-oncology controversies

Learning Objectives:

At the end of this session participants will be able to:

evaluate diagnostic and management strategies for young patients presenting with NSTEMI and MINOCA, including the use of multimodality imaging and the role of invasive versus non-invasive approaches;
compare and select appropriate therapeutic interventions for arrhythmia management, distinguishing between indications for antiarrhythmic medications versus catheter ablation in diverse patient scenarios; and
formulate evidence-based approaches to the prevention, monitoring, and management of cardiotoxicity in oncology patients with pre-existing cardiovascular disease, incorporating the use of biomarkers, imaging, and prophylactic therapies.